TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Nebulized Heparin for COVID19-associated Acute Respiratory Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients admitted with confirmed COVID-19 receiving mechanical ventilation for ARDS (paO2/FiO2 ratio =300) within 48 hours~Exclusion Criteria:~* Allergy to heparin~* Any history of heparin-induced thrombocytopenia~* High risk of bleeding (platelet count \< 50,000/µL or international normalized ratio \> 1.5)~* Patients with known bleeding disorders (i.e. hemophilia or von Willebrand Disease)~* Active bleeding~* Pulmonary bleeding during this hospital admission (Pulmonary bleeding is frank bleeding in the lungs, trachea or bronchi with repeated hemoptysis, or requiring repeated suctioning, and temporally associated with acute deterioration in respiratory status)~* Neurosurgical procedures during this hospital admission or such procedures are planned~* Epidural catheter in place~* Any history of intracranial, spinal or epidural hemorrhage~* Tracheostomy in place~* Cervical spinal cord injury associated with reduced long-term ability to breathe independently~* Spinal or peripheral nerve disease with a likely prolonged reduction in the ability to breathe independently~* Receiving extra-corporeal membrane oxygenation or continuous renal replacement therapy~* Usually treated with hemodialysis or peritoneal dialysis for end-stage renal failure~* Death is deemed imminent or inevitable or there is an underlying disease with a life expectancy of fewer than 90 days~* Pregnant or might be pregnant.~* Objection from the treating clinician~* Consent refused by the patient or substitute decision maker.~* History of thrombosis (VTE or cardiovascular event)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nebulized heparin (Type: EXPERIMENTAL): Nebulized heparin 25,000 units in 3 mL inhalation every 6 hours
- Nebulized placebo (Type: PLACEBO_COMPARATOR): Sodium chloride 0.9% 5 mL inhalation every 6 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Telephone vs. Voice Over IP Speech Comprehension in Hearing Aided Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Bluetooth enabled hearing aid (Nucleus 6 CI or a GN Resound hearing aid) compatible to the phone clip~* Use of hearing aid for ≥ 3 months.~* Native German speaker~Exclusion Criteria:~* Mentally or physically unfit to participate~* Vulnerable Person

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional acoustic telephony (Type: PLACEBO_COMPARATOR): Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with acoustic transmission of the speech signal.
- Conventional bluetooth telephony (Type: ACTIVE_COMPARATOR): Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
- VoIP acoustic telephony (Type: ACTIVE_COMPARATOR): Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with acoustic transmission of the speech signal.
- VoIP bluetooth telephony (Type: ACTIVE_COMPARATOR): Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 3rd Dose Vaccine in Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age and older~* Patients who had received a solid organ (kidney, liver, lung, heart, and pancreas) transplant patient from living or deceased donors.~* Patients with active graft with at least one immunosuppressive medication~* Completed two doses of BNT162b2 vaccination at least 28 days ago~Exclusion Criteria:~* Patient with non-active graft~* Any significant side effect with previous COVID-19 vaccination~* Within 28 days of BNT162b2 vaccine completion~* Already received more than and equal to three doses of COVID-19 vaccination~* Previously received COVID-19 vaccine other than BNT162b2 vaccine~* Previously received monoclonal Antibody treatment that are specifically directed against the spike protein for Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV)-2 such as Mab, Bamlanivimab, etesevimab, Casirivimab, imdevimab, Sotrovimab and/or any combination.~* Thrombocytopenia (if less than 50,000 per microliter 30 days prior vaccination)~* History of Capillary Leak Syndrome~* Adults unable to consent~* Individuals who are not yet adults (younger than 18 year old)~* Vulnerable patients (prisoners)~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BNT162b2 vaccine Group (Type: EXPERIMENTAL): Participants in this arm will receive one booster dose of the BNT162b2.
- JNJ-78436735 vaccine Group (Type: EXPERIMENTAL): Participants in this arm will receive one booster dose of the JNJ-78436735

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* proteinuria \> 1 g/day with ramipril 5 + valsartan 80 mg/day for 2 months~* proteinuria changes \< 50% on 3 separate dosages over 2 months.~Exclusion criteria:~* age \< 18 or \> 80 years systolic BP \< 110 or ≥ 140 mmHg, serum creatinine \> 250 mmole/L~* serum creatinine increase on ramipril + valsartan \> 20%~* intolerance to ACEI or ARB

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Remote Ischemic Conditioning and Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Elective on-pump CABG surgery~* Informed consent~Exclusion Criteria:~* Prior cardiac surgery (Re-operations)~* Prior atrial fibrillation~* Use of class 1 or 3 anti arrhythmic medication or digoxin Use of intermittent aortic cross clamping during surgery~* Age \<18 years~* Left ventricular ejection fraction ≤30%~* Serious pulmonary disease (resting pO2 \<90% at room air)~* Renal failure (clearance \<30 ml/min as calculated using the Modification of Diet in Renal Disease formula)~* Liver failure~* Use of the sulfonylurea derivative glibenclamide (this drug is known to block any preconditioning stimulus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preconditioning (Type: EXPERIMENTAL): The remote ischemic stimulus will be applied after induction of anaesthesia, but before cardiopulmonary bypass.
- Postconditioning (Type: EXPERIMENTAL): The remote ischemic stimulus during cardiopulmonary bypass.
- Pre and postconditioning (Type: EXPERIMENTAL): The remote ischemic stimulus will be applied twice, after induction of anaesthesia and during cardiopulmonary bypass.
- Control (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of 6 Weeks TOTUM-070 on Lipid Metabolism and Cardiovascular Health in Individuals at Increased Cardio-metabolic Risk

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Body mass index (BMI) between 18.5 and 35 kg/m²~* Moderate hypercholesterolemic subject without any clinical symptoms of hypercholesterolemia (xanthoma, recurrent chest and/or leg pain...) and not requiring immediate pharmacological lipid-lowering treatment according to the current recommendations (European Society of Cardiology /European Atherosclerosis Society, 2019)~* Fasting blood LDL cholesterol level (using Friedewald estimation method) between 1.3 and 1.9 g/L~* Fasting blood triglycerides level ≤ 2.2 g/L~Main Exclusion Criteria:~* Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal dysfunction or other metabolic disorder needing a dose adjustment in drug intervention according to the professional recommendations~* Suffering from an uncontrolled arterial hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg)~* With a history of ischemic cardiovascular event~* Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, ongoing hepatic or biliary disorders, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or gastrointestinal disorders found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease)~* Fasting glucose plasma concentration \> 1.26 g/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- TOTUM-070 (Type: EXPERIMENTAL): Experimental active diet supplement TOTUM-070 taken 2 times per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Test the Efficacy of the PRO-SELF® Plus Pain Control Program to Reduce Pain in Outpatients With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Patient Inclusion Criteria:~* any type of cancer pain, including bone metastasis, somatic or visceral pain, with repeated pain ≥ 3 on a 0-10 Numeric Rating Scale (NRS) during the last week~* estimated life expectancy of \> 6 months as assessed by the physician~* 18 years of age or older~* being able to understand, read and write German~* access to a telephone~* living within one hour's driving distance of a participating site~Adapted inclusion criterion (from 01 Sept 2016 on)~- any type of cancer pain, including bone metastasis, somatic or visceral pain, with repeated pain ≥ 3 on a 0-10 Numeric Rating Scale (NRS) during the last week~Patient Exclusion Criteria:~* cognitive dysfunction (as assessed by the physician) that would preclude full participation~* hearing impairment that precludes telephone conversations~* solely neuropathic pain (as assessed by the physician)~* participation in another clinical trial that requires extended hospitalizations (\> 2 weeks)~* participation in another clinical trial that could exert an influence on the study intervention's effectiveness~* Family caregiver (FC) involved in pain management who declines to participate in the intervention (FCs are not required to participate in the study as participants).~FC Inclusion Criteria:~* 18 years of age or older~* being able to understand, speak and write German; and~* willingness to participate in all intervention sessions~FC Exclusion Criterion:~* hearing impairment that precludes understanding telephone conversation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): Adapted German PRO-SELF© Plus Pain Control Program
- Control Group (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 or over,~* Who had been included in the Transpeg 1 study,~* Non-responders after a three month peginterferon alfa-2a / ribavirin bitherapy or with a recurrent disease during the Transpeg 1 maintenance phase, whatever the randomization group (ribavirin or placebo),~* With a positive qualitative PCR at inclusion,~* With a METAVIR histologic score of 1 or more on the last biopsy (done within the 6 months preceding inclusion),~* Treated with tacrolimus for at least 6 months prior to inclusion,~* Having given a written informed consent.~Exclusion Criteria:~* Treatment with peginterferon or ribavirin within the 6 months preceding inclusion,~* Severe hepatocellular failure or decompensated cirrhosis,~* Acute graft rejection within the two months preceding inclusion, or signs of chronic rejection on the last biopsy, or retransplantation since inclusion in the Transpeg 1 study,~* Treatment with cyclosporin for more than 6 months during the 24 months preceding inclusion,~* Treatment with a mTOR inhibitor or with another investigational immunosuppressive drug,~* Positive serology for HIV or HBV,~* Cancer (or history of other malignancy during the last 5 years) except patients transplanted for hepatocellular carcinoma and basocellular or excised spinocellular carcinoma,~* Serious concomitant disease or acute or chronic disorder, other than the current transplant, treated with steroids,~* Serious cardiac pathology within the last 6 months,~* Women with ongoing pregnancy or breast-feeding,~* Serious chronic renal failure (creatinine clearance \< 30 ml/mn),~* Haemoglobin \< 10 g/dl, platelets \< 50 000/mm3 or neutrophils \< 1000 / mm3,~* Abnormal TSH values,~* Inability to cooperate or to communicate with the investigator,~* Contraindications to ribavirin, peginterferon alfa-2a or cyclosporin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ciclosporin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Embozene Microspheres for Uterine Fibroid Embolization (UFE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is able to provide informed consent and must sign the Institutional Review Board approved Informed Consent Form.~* Pre-menopausal women age 30-50 years at time of enrollment~* Have been selected forUterine Fibroid Embolization (UFE) prior to entry to the study.~Exclusion Criteria:~* Patient has a history of pelvic malignancy~* Patient has an abnormal Pap smear within 12 months of the planned Uterine Fibroid Embolization procedure~* Patient with coexisting condition that might explain abnormal bleeding (including endometrial hyperplasia and adenomyosis) or pelvic pain (including endometriosis and ovarian cysts).~* Is at substantial risk for the need of organ transplantation, such as renal insufficiency.~* Patient has evidence of current or recent pelvic inflammatory disease or uterine infection.~* Patient with a severe contrast allergy or renal insufficiency that would represent a contradiction to the administration of iodine-based contrast agents.~* Patients unable to comply with the follow-up requirements of the study.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Embozene® Microspheres (Type: EXPERIMENTAL): Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
- Embosphere® (Type: ACTIVE_COMPARATOR): Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Young People and Illness Management and Recovery (IMR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria Patients:~Outpatient units:~* Included in the IMR group in one of the outpatient clinics~* Able to give informed consent~Inpatient unit (focus group):~* 13-17 years of age~* Current or previous patient~* Able to understand and speak Norwegian~* Able to give informed consent~Exclusion criteria (inpatient unit)~* Younger than 13 years~* Mental retardation~* Manic phase~Inclusion Criteria: IMR therapists:~* IMR therapist leading IMR treatment groups in one of the participating outpatient clinics~* Trained or training in IMR~* Employed at the Department for Child and Adolescent Mental Health Services at Akershus University Hospital.~Inclusion Criteria: Other staff members~• Employed at the Department for Child and Adolescent Mental Health Services at Akershus University Hospital.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- IMR patients (Type: None): Patients from outpatient clinics receiving IMR from trained IMR therapists and IMR therapists in training.
- IMR therapists and other staff (Type: None): Clinic leaders, IMR therapists and other staff participating in semi-structured individual or group interviews.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients at least 18 years of age~* Receiving Wake Forest Baptist Health Outpatient parenteral antimicrobial therapy (OPAT) services~* Will receive vancomycin therapy from Wake Forest Baptist Health Specialty Home Infusion Pharmacy~* Planned therapy with vancomycin in the outpatient setting for at least 2 weeks in duration~* Prescribed vancomycin with a frequency of either every 12 hours or every 8 hours dosing at the time of enrollment~Exclusion Criteria:~* Presence of diseases or conditions known to affect the pharmacokinetics of vancomycin: Pregnancy/Ascites/Burn injury/Cystic fibrosis /Weight greater-than or equal-to 150 kg~* Pre-existing leukopenia: White Blood Cell (WBC) \< 4,000 x 103 cells/µL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- continuous infusions (CI) group (Type: ACTIVE_COMPARATOR): CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge
- Intermittent infusion (II) group (Type: ACTIVE_COMPARATOR): Inpatient study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven gastric adenocarcinoma: uT1,uT2, uT3, Nx, M0~2. No prior chemotherapy~3. Patients of full age, independent of gender ECOG ≤ 2~4. No dissemination of the tumor confirmed by CT of the lung and the abdomen.~5. Signed Consent form of the Patient agreeing to investigations~6. Leucocytes \> 3.000/µl~7. Thrombocytes \> 100.000/µl~8. Creatinine ≤ 1.5mg/dl and or Clearance \> 60 ml/min~9. informed consent of the patient~10. normal ejection-fraction of the heart~Exclusion Criteria:~1. Dissemination of the tumor or non-resectable primary tumor~2. Malignant secondary disease \< 5 years in the past (Exception: in-situ-carcinoma of the cervix and appropriately treated basal cell carcinoma of the skin)~3. Patient not of full age~4. Inflammatory chronic bowel disease~5. Inclusion of the patient in a different study~6. Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- positive cytology with HIPEC (Type: EXPERIMENTAL): gastric cancer cytology positive with HIPEC Mytomycin and cisplatin intraoperative
- positive cytology without HIPEC (Type: NO_INTERVENTION): gastric cancer cytology positive without HIPEC
- negative cytology without HIPEC (Type: NO_INTERVENTION): gastric cancer with negative cytology

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues